Participants in CPhI China 2016 June 21-23 at the Shanghai New International Expo Centre have been given a special opportunity – a tour of PaizaBio’s CGMP-qualified, aseptic fill-and-finish facilities in Hangzhou. The facility is owned by Ausia BioTech, PaizaBio’s strategic partner in China.
PaizaBio is a consultancy and CMO to multi-national pharmaceutical companies seeking to establish an immediate manufacturing presence in China’s burgeoning drug market. In May, PaizaBio signed an agreement with Taiwan-based JHL Biotech, Inc. (Stock Code: 6540.TWO) to provide fill-finish services for multiple JHL projects in Hangzhou.
Scheduled for June 23rd, the unique, day-long tour is ideally timed given the CFDA’s policy updates made in late May allowing expanded use of contract manufacturing organizations (CMOs) that meet CGMP standards for drug manufacturing. Guests will get an in-depth immersion into one of China’s most sophisticated CMOs.
The tour is hosted by CPhI China and PaizaBio and is open to attendees of China’s premier pharmaceutical industry event. The event includes transportation to and from Hangzhou, lunch and a guided tour with these highlights:
- Aseptic Fill-and-Finish Operation with eight high-speed, automated filling and stoppering lines and temperature-controlled warehouse. Annual capacity of 300 million units.
- Freeze Drying (Lyophilization) Cycle Research and Development Laboratory
- Trans-Pacific Aseptic Institute of Training™ (TPA-IT), China’s only “sterile university” dedicated to training people from government and industry to CGMP standards for aseptic manufacturing. TPA-IT held its first session in March 2016 with more than 20 students.
- BAO-Gong® Real-Time Remote Manufacturing Monitoring System
The tour will be led by multi-lingual PaizaBio alliance management professionals experienced in the Chinese and global pharmaceutical industries. We welcome all guests to tour, ask questions and enjoy learning more about our CGMP-qualified operations in beautiful Hangzhou!